Cara Therapeutics (NASDAQ:CARA) reported Q4 EPS of ($0.56), $0.24 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $14.54 million.
https://www.investing.com/news/cara-therapeutics-misses-q4-eps-by-24c-432SI-3023291
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.